Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation.
Journal
Drugs in R&D
ISSN: 1179-6901
Titre abrégé: Drugs R D
Pays: New Zealand
ID NLM: 100883647
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
06
03
2022
pubmed:
14
5
2022
medline:
9
6
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Hydroxychloroquine was widely used during the severe acute respiratory syndrome coronavirus 2 pandemic as an antiviral drug. Most previous pharmacokinetic/pharmacodynamic studies on hydroxychloroquine were conducted on healthy volunteers or patients receiving long-term therapy. There are no studies on the elimination of hydroxychloroquine after short-term treatments. Hydroxychloroquine is known to have a pro-arrhythmic effect through QT interval prolongation, but data in this setting are not conclusive. Our aims were to estimate the time needed for hydroxychloroquine concentrations (C We collected blood samples and electrocardiograms of patients who underwent short-term therapy with hydroxychloroquine during drug intake and after discontinuation. Hydroxychloroquine concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry and analysed with a linear regression model to estimate the elimination time of the drug after its discontinuation. We conducted a multivariate analysis of the corrected QT interval correlation with C Our data suggest that short-term hydroxychloroquine courses can generate significant C The study confirms the long half-life of hydroxychloroquine and its effect on the corrected QT interval even after short-term courses of the drug. This can inform the clinician using hydroxychloroquine treatments that it would be safer to start or re-initiate treatments with corrected QT interval-prolonging potential 16 days after hydroxychloroquine discontinuation.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Hydroxychloroquine was widely used during the severe acute respiratory syndrome coronavirus 2 pandemic as an antiviral drug. Most previous pharmacokinetic/pharmacodynamic studies on hydroxychloroquine were conducted on healthy volunteers or patients receiving long-term therapy. There are no studies on the elimination of hydroxychloroquine after short-term treatments. Hydroxychloroquine is known to have a pro-arrhythmic effect through QT interval prolongation, but data in this setting are not conclusive. Our aims were to estimate the time needed for hydroxychloroquine concentrations (C
METHODS
METHODS
We collected blood samples and electrocardiograms of patients who underwent short-term therapy with hydroxychloroquine during drug intake and after discontinuation. Hydroxychloroquine concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry and analysed with a linear regression model to estimate the elimination time of the drug after its discontinuation. We conducted a multivariate analysis of the corrected QT interval correlation with C
RESULTS
RESULTS
Our data suggest that short-term hydroxychloroquine courses can generate significant C
CONCLUSIONS
CONCLUSIONS
The study confirms the long half-life of hydroxychloroquine and its effect on the corrected QT interval even after short-term courses of the drug. This can inform the clinician using hydroxychloroquine treatments that it would be safer to start or re-initiate treatments with corrected QT interval-prolonging potential 16 days after hydroxychloroquine discontinuation.
Identifiants
pubmed: 35553396
doi: 10.1007/s40268-022-00387-2
pii: 10.1007/s40268-022-00387-2
pmc: PMC9103606
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-163Informations de copyright
© 2022. The Author(s).
Références
Int J Clin Pract. 2021 Jul;75(7):e14182
pubmed: 33759318
Drug Saf. 2018 Oct;41(10):919-931
pubmed: 29858838
Arthritis Care Res (Hoboken). 2016 Sep;68(9):1295-302
pubmed: 26749299
J Clin Pharmacol. 1994 Nov;34(11):1088-97
pubmed: 7876401
Br J Clin Pharmacol. 1988 Sep;26(3):303-13
pubmed: 3179169
Am J Med. 1983 Jul 18;75(1A):11-8
pubmed: 6408923
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662
pubmed: 32347743
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069
pubmed: 32936266
Therapie. 2020 Jul - Aug;75(4):371-379
pubmed: 32418730
Heart Rhythm. 2020 Nov;17(11):1930-1935
pubmed: 32610165
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
Arthritis Rheum. 2006 Oct;54(10):3284-90
pubmed: 17009263
Clin Pharmacol Ther. 2019 Apr;105(4):943-953
pubmed: 30447156
Toxicol Sci. 2021 Apr 12;180(2):356-368
pubmed: 33483756
Br J Pharmacol. 2022 Jun;179(11):2631-2646
pubmed: 34837219
Heart. 2017 Nov;103(22):1821-1829
pubmed: 28490617
J Rheumatol. 2015 Nov;42(11):2092-7
pubmed: 26428205
Infect Dis Ther. 2020 Sep;9(3):561-572
pubmed: 32740858
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
J Pharmacol Exp Ther. 2001 Apr;297(1):437-45
pubmed: 11259572
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041
pubmed: 32936252
J Am Coll Cardiol. 2020 May 26;75(20):2623-2624
pubmed: 32283123
Eur J Pharmacol. 2021 Dec 15;913:174632
pubmed: 34785211
Cardiovasc Toxicol. 2021 Apr;21(4):314-321
pubmed: 33387252
Arthritis Rheumatol. 2020 Mar;72(3):448-453
pubmed: 31532077
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Clin Transl Sci. 2021 May;14(3):1133-1146
pubmed: 33620150
Br J Clin Pharmacol. 1989 Jun;27(6):771-9
pubmed: 2757893
Ann Rheum Dis. 2007 Jun;66(6):821-4
pubmed: 17324970
Pharmacotherapy. 2018 Aug;38(8):813-821
pubmed: 29882591
Ther Drug Monit. 2003 Dec;25(6):671-81
pubmed: 14639053
Circ Arrhythm Electrophysiol. 2020 Nov;13(11):e008890
pubmed: 32991202
Nat Med. 2020 Jun;26(6):808-809
pubmed: 32488217
Therapie. 2021 Jul-Aug;76(4):285-295
pubmed: 33558079
Antimicrob Agents Chemother. 2012 Jun;56(6):3261-70
pubmed: 22391528